[120 Pages Report] Cerebrospinal fluid (CSF) management involves the use of devices such as shunts and external drainage systems to maintain the flow of CSF and drain excess fluid from the brain. Over the years, the disease burden of hydrocephalus has increased considerably, increasing the demand for CSF management devices as a method of treatment. The high prevalence of hydrocephalus and the subsequent increase in the number of shunting procedures and the growing geriatric population are major factors driving the market growth. The growing healthcare market in developing economies is also expected to provide growth opportunities for players in the market. On the other hand, the dearth of trained professionals and complications related to CSF shunts may challenge market growth to a certain extent.

The cerebrospinal fluid (CSF) management market is projected to reach USD 1,561.1 million by 2022 from an estimated USD 1,256.3 million in 2017, at a CAGR of 4.4%. The market is further segmented based on products, end-users, and regions.

Shunts to dominate the cerebrospinal fluid (CSF) management market in

The large market share of this product segment can be attributed to the growing number of shunting procedures performed worldwide as well as the increasing number of revisions shunt surgeries owing to shunt malfunction and infection.

Ventriculoperitoneal segment dominated the CSF shunts market in 2017

On the basis of type, the shunts market is segmented into ventriculoperitoneal (VP), ventriculoatrial (VA), ventriculopleural (VPL), and lumboperitoneal (LP) shunts. This segment is also estimated to register the highest CAGR during the forecast period. Factors propelling the growth of this segment include the advantages associated with these shunts over other shunts, such as reduced chances of revision surgery and the lower average length of hospital stay.

Adjustable valve shunts accounted for the largest share of the CSF shunts market in

On the basis of valve type, the shunts market is categorized into fixed and adjustable. The adjustable segment commanded the largest share of the shunts market in 2017 and is also estimated to register the highest CAGR during the forecast period. The major factor contributing to the growth of this market segment is the reduced intervention for the alteration of CSF flow along with their rising adoption in developed countries.

External ventricular drainage to command the largest share of external drainage systems market in 2017

On the basis of type, the external drainage systems market is categorized into external ventricular drainage (EVD) systems and lumbar drainage (LD) systems. The external ventricular drainage systems segment commanded the largest share of the external drainage systems market in 2017 and is also estimated to register the highest CAGR of during the forecast period. This can be attributed to its growing application for the treatment of acute hydrocephalus and obstructive hydrocephalus.

Pediatric end-user segment dominated the cerebrospinal fluid management market in 2017

On the basis of end-users, the market is categorized into pediatric, adult, and geriatric end users. The pediatric segment commanded the largest share of the cerebrospinal fluid (CSF) management market in 2017 and is also estimated to register the highest CAGR during the forecast period. This can be attributed to the high prevalence of congenital hydrocephalus along with the rising number of shunting procedures in the pediatric population.

APAC to account for the highest market growth during the forecast period

Asia Pacific is the third-largest market for CSF management and is slated to register the highest CAGR during the forecast period. Factors contributing to this growth include the high prevalence of congenital hydrocephalus in China, a growing geriatric population in Japan, and increasing medical tourism in India and several RoAPAC countries.

Market Dynamics

Driver: High prevalence of hydrocephalus and the subsequent increase in the number of shunting procedures

Hydrocephalus affects a large number of people worldwide. According to the Hydrocephalus Association, more than 1 million people in the US are reportedly suffering from hydrocephalus. Similarly, 700,000 older Americans are living with normal pressure hydrocephalus (NPH). According to CURE Hydrocephalus estimates, over 400,000 newborns suffer from infant hydrocephalus around the globe each year. Moreover, congenital hydrocephalus affects a huge number of infants worldwide.

Opportunity: Growing healthcare market in developing economies

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. The World Economic Forum estimates that these emerging economies will account for around one-third of the global healthcare expenditure by 2020. Moreover, more than half of the world�s population resides in India and China, owing to which these countries are home to a large patient pool.

Hydrocephalus affects a large number of people in developing countries. According to CURE Hydrocephalus, of the total number of children born with hydrocephalus globally, 79% are born in the developing world. It was estimated that there were over 6,000 new cases of hydrocephalus reported per year in East Africa. According to the International Federation for Spina Bifida and Hydrocephalus, over 375,000 new cases of infant hydrocephalus are reported in sub-Saharan Africa each year.

The presence of such a huge patient base in the emerging economies, along with rising healthcare expenditure, is expected to serve as an opportunity for players in the CSF management market.

Challenge: Complications related to CSF Shunts

Hydrocephalus can be treated with a shunt system; however, this treatment often includes complications. The most common shunt complications include malfunction, infection, and shunt obstruction. According to Pediatric Emergency Medicine Reports, about 40% of shunts fail within the first year and 56�80% by 10 years. Additionally, between 8�10% of shunts eventually become infected. Shunt malfunction can lead to an acute increase in intracranial pressure (ICP), causing irreparable impairment of the brain.

Moreover, according to the Hydrocephalus Association, an estimated 50% of shunts in the pediatric population fail within two years of placement and often require repeat surgery. These shunt failures account for more than 15,000 pediatric hospital admissions per year, with an estimated mortality rate of 1�2% (Source: Pediatric Emergency Medicine Reports). According to Seattle Children's Hospital, each year, about 38,000 surgeries are performed to replace failed shunts in the US.

Scope of the Report

Report Metric Details Market size available for years 2015 � 2022 Base year considered 2016 Forecast period 2017 � 2022 Forecast units Million/Billion (USD) Segments covered Product, End User, and Region Geographies covered North America, Europe, APAC, RoW (South America, Middle East, and Africa) Companies covered Key market players, including

Medtronic, Integra, DePuy Synthes,B.Braun, Spiegelberg GmbH & Co. KG, Sophysa (A subsidiary of tkb group), Natus Medical Incorporated, Dispomedica gmbh, Deltasurgical, Argi Grup, Moller Medical GMBH, G. SURGIWEAR LTD, Wellong Instruments Co., Ltd.

The research report categorizes the Cerebrospinal Fluid Market to forecast the revenues and analyze the trends in each of the following sub-segments:

Cerebrospinal Fluid Market, By Product

CSF Shunts

External Drainage Systems

Cerebrospinal Fluid Market, By End User

Pediatric

Adult

Geriatric

Cerebrospinal Fluid Market, By Geography

North America

Europe

Asia Pacific (APAC)

RoW

Key Market Players

Medtronic, Integra, DePuy Synthes, and B.Braun.

Recent Developments

In 2018, Aesculap, a subsidiary of B. Braun entered into a joint venture with Christoph Miethke GmbH & Co. KG. to form B. Braun Miethke GmbH & Co. KG. The joint venture is expected to strengthen B. Braun's offering in the CSF management market.

In 2017, Integra LifeSciences acquired Johnson & Johnson Codman Neurosurgery, this acquisition aimed at enhancing Integra�s product portfolio and position in the neurosurgery market.

In 2017, Natus medical acquired certain neurosurgery business assets from Integra LifeSciences. The businesses acquired include the global Camino ICP monitoring product line along with its San Diego manufacturing facility, and the US rights to Integra's fixed pressure shunts and Codman's DURAFORM dural graft implant, standard EVD catheters, and CSF collection systems. This acquisition is expected to strengthen the company�s offering in CSF management market.

In 2014, B. Braun Medical opened a new subsidiary, B. Braun of Canada. This helped expand the company�s presence in the North American market.

Critical questions the report answers:

What are the upcoming trends for the Cerebrospinal Fluid Market?

Which segment provides the most opportunity for growth?

Who are the leading vendors operating in this market?

What are the opportunities for new market entrants?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst